CRI CENTRE de RECHERCHE sur l'INFLAMMATION

Inserm

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

Tarik Asselah

Université de Paris,
INSERM UMR 1149,
Service d'Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France.

Hepatitis Delta Prevalence in France

From 2010 to 2014
HDV in France : 3-4% HBsAg+ (150-200.000)
~ 6000 to 8000 patients HDV+



DeltaVir Study

Biothèque CNR 2000-13
4815 patients VHD+
Dossier médical
(inclusion-suivi)

→ 3702 patients VHD+
Pas de dossier
Dossier sans suivi

Cohorte Deltavir
1112 patients VHD+
ARN VHD+ (88%)
hospitalisés

34 centres
18 centres APHP
785 pts(70%)





France:
G1 dominant (76%) : G1 Eu/As > G1 Af
G5,G6,G7,G8 africains

Roulot D et al. J Hepatol 2020

Bulevirtide Early Access RWD from France

Multicenter, prospective and retrospective observational real-world data of BLV 2mg



Baseline Characteristics	BLV 2mg n=77
Mean age, years (SD)	42 (12)
Men, n (%)	54 (70)
Cirrhosis, n (%)	48 (62)
Mean ALT, IU/L	69 (36)
Median HDV RNA, log IU/mL (IQR)	6.26 (1.3)
Undetectable HBV DNA, n/N (%)	49/72 (68)
HBeAg+, n (%)	9 (8)
Current NUC use, n (%)	64 (83)
HIV infection, n (%)	14 (18)

Adapted from de Ledinghen V, et al. AASLD 2021. Oral 21

France Early Access Program

Virologic Response Over 12 Months

Changes in HDV RNA Levels Over Time (PP)



HDV RNA Response (PP)

Undetectable HDV RNA or ≥2 log IU/mL decline



BLV 2mg monotherapy led to considerable HDV RNA declines

PP, Per protocol analysis. Study not powered to compare the two treatment regimens
de Ledinghen V, et al. AASLD 2021. Oral 21

Biochemical Response Over 12 Months

Changes in ALT Over Time (PP)



Normal ALT Level (PP)



High levels of normal ALT were achieved with BLV 2mg in this real world cohort

PP, Per protocol analysis.
Normal ALT defined as <40 IU/L. Missing does not equal failure.
Adapted from de Ledinghen V, et al. AASLD 2021. Oral 21

Important for our patients : Need to Cure HDV

- HDV might be under-estimated at > 60 million infected individuals (Stockdale et al. 2019, Miao et al. 2019)
- HDV increases risk of cirrhosis (Fattovich et al, Seminars in Liver Diseases 2003)
- Previous treatment recommendation of HDV is PEG-IFN-alfa for 48 weeks. For patients who failed PEG-IFN-alfa, there has been no therapeutic option available until recently.
- First EU conditionally-approved drug to treat HDV available in 2020: Bulevirtide (Hepcludex®): However 50% non responders at 48 weeks
- Drugs in development for HDV: prenylation inhibitors, peginterferon lambda and HBsAg secretion inhibitors.